Rainbow carrot juice: a new weapon against diabetes?
NCT ID NCT05319548
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at how pigments in different colored carrots (red, purple-red, and purple) affect the body's absorption of vitamin A and other nutrients. Twelve healthy adults drank each type of carrot juice over several weeks, and researchers measured changes in their blood. The goal was to see if combining certain pigments could boost health benefits, like antioxidant activity and blood sugar control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Carrot juice (red, purple-red, or purple)
- What this could lead to
- If successful, this could help design foods that maximize the health benefits of plant pigments, potentially aiding diabetes prevention.
- What could go wrong
- This is a small, early-stage study with only 12 healthy participants, so results may not apply to the general population or those with health conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UW-Madison Department of Nutritional Sciences
Madison, Wisconsin, 53706, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test